Key clinical point: Patients with hidradenitis suppurativa (HS) are at an increased risk of long-term opioid use.
Major finding: Patients with HS were more likely to use opioids for at least a year, compared with a control group (adjusted odds ratio, 1.53, 95% confidence interval, 1.20-1.95; P less than .001).
Study details: Retrospective analysis of nearly 829,000 patients in a control group and 22,277 with HS who were tracked over a 10-year period.
Disclosures: An educational grant to a study author from AbbVie partially funded the study. No other study funding is reported. The lead author had no disclosures; one author disclosed having received grants and personal fees from AbbVie and UCB during the study.
Reddy S et al. JAMA Dermatol. 2019 Sep 11. doi: 10.1001/jamadermatol.2019.2610.